Healthymagination at Ge Healthcare Systems
Healthymagination at Ge Healthcare Systems
Healthymagination at Ge Healthcare Systems
TERM 2 : CSTR
TERM 2 : CSTR
Q1. WHAT SHOULD TOM GENTILE DO? SHOULD HE GIVE THE GREEN LIGHT OR HALT FURTHER
COMMERCIALIZATION OF HEP-ECHO? TEE-MAX, ULTRA-LIPO? OMEGA?
Product
Cost/EconomicsEvaluation
7xmarginavailable.Thus,15%
costbenefitavailable.
Hep Echo
LowBreakevenpointof~350
units.
TEEMax
AccessEvaluation
Strategy
1.Bychargingalowprice(ashuge
1.Bestinclassimaging
marginavailable)theproductcan SustainingStrategy
performancesolution.2.Great
bemadeavailabletomidtier
Bringingbetter
improvementintermsof
hospitals.2.GEalreadyhasa
valuetoexisting
effectivity.3.Cannotquantifybut
NationalAccountsSalesTeamin
customers
>15%improvementexpected.
place.
Cannotchargeahighpriceas
Philipsisalreadyinthemarket
Cannotmeetclinicallyevident15%
withsimilarproduct.
qualityimprovementwithout
furtherinnovation.
Breakevenquantityis~1500
units.
Duetohighmargin15%cost
reductionpossible.
Noinformationavailable.
SustainingStrategy
Bringingbetter
valuetoexisting
customers
Go/NoGo
verdict
GO
NOTGO
Othercompetitorsinthemarket Lowenddisruption
providingthesimilarproductina
strategy offer
Lackofclinicallyrelevantbenefit. spalikeenvironment.Thus,no customersagood
improvementpossiblein
enoughproductat
accessiblity.
lowerprices
GO
NewMarket
BreakEvenpoint~4000units.
disruptionStrategy
Lowmarginhighvolumeproduct.
Nocompetitioninthemarket.A
Increasedthecapablity ofmidwifes
Offernon
Provideabetteralternative(Mid
totallynewuntappedmarket.
tounderstandrisksofpregnancy.
consumersa
wife~$45)toendcustomers
Thus,itimprovesaccessiblity.
simple,convenient
reducingprice90%
product.
GO
UltraLipo
Lowbreakevenpointof~100
units.3.$1Billionindustry.
Omega
QualityEvaluation
TERM 2 : CSTR
Q2. WHAT ARE THE PRIMARY AREAS OF CONCERN FOR EACH OF THE PRODUCT CONCEPTS USING RYG
NPI EVALUATION CHART? WHAT ARE THE KEY VALUES OF USING THIS PROCESS?
HEP
ECHO
REASON
TEE
MAX
REASON
ULTRA
LIPO
REASON
OMEGA
REASON
PRODUCT
ECONOMIES
EVIDENCE
GENERATION
SUPPLY CHAIN
MARKET ACCESS
No discussion in case.
SALES AND
DISTRIBUTION
SERVICE AND
INSTALLATION
VALUE CREATION
TECHNOLOGY
ECONOMIC VALUE
QUANTIFICATION
VALUE DELIVERY
TERM 2 : CSTR
Q3. USING THE PIM TOOL HOW WOULD YOU EVALUATE ULTRASOUND PORTFOLIO PRODUCT? WHERE
WOULD EACH OF THE NEW PRODUCT CONCEPT BE PLACED ON THIS MAP? HOW IS
HEALTHYMAGINATION IS LIKELY TO ALTER THE DISTRIBUTION OF THE MAP?
TechnologicalUncertainity
Rating
Range
Reasons
Rating
Range
Reasons
HepEcho $36Million
0 2
BasedonLOGIQE9
Arcitecture
0 2
B2BMarketspace
TEEMax $20Million
2 4
SomeRnD requiredto
makeproductcompetitive
0 2
B2BMarketspace
UltraLipo $10Million
4 6
Newproduct
4 6
0 2
Fairlysimplerproduct
4 6
Investment
MarketUncertainity
Omega
$6Million
NewSegment/Newtype
ofcustomers(Spa
Owners)
NewSegment/Newtype
ofcustomers(MidWives)
TERM 2 : CSTR
Is it a Branding or innovation
Strategy?
Both
Branding : It is similar to
CSR activity where in
corporate is trying to
create a caring image in the
minds of its customer.
Innovation: New product
development for customer
delight.
Why now?
Risks?